# PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

> **NCT03755440** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 6 (actual)

## Conditions studied

- Gastric Cancer Stage IV
- EBV

## Interventions

- **DRUG:** PD-1 antibody (SHR-1210)

## Key facts

- **NCT ID:** NCT03755440
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755440, "PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03755440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*